The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:5
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [21] Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
    Huang, Xiaoyan
    Wu, Miaohui
    Huang, Baoliang
    Zhang, Yi
    FRONTIERS IN MEDICINE, 2025, 12
  • [22] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [23] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [24] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
  • [25] Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis
    Kumar, Jai
    Mohsin, Sana
    Hasan, Misha
    Bilal, Abdur Raheem
    Ali, Kumail Mustafa
    Umer, Ahmed
    Hadi, Dua Zehra Mohammad
    Nandlal, Sanjna
    Kumar, Sarwan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (01)
  • [26] Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
    Mohamed, Islam
    Gautam, Misha
    Abosheaishaa, Hazem
    Hussain, Sophia
    Kumar, Kopal
    Kotak, Anaya
    Baugh, Macy
    Qureshi, Raabia
    Jaber, Fouad
    Dahiya, Dushyant Singh
    Alba, Laura
    Duong, Nikki
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (11) : 1259 - 1266
  • [27] The Effects of Testosterone Replacement Therapy in Adult Men With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis
    Mahmoud, Maya
    Kawtharany, Hassan
    Awali, Mohamed
    Mahmoud, Nadine
    Mohamed, Islam
    Syn, Wing-Kin
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (01)
  • [28] Prevalence of metabolic dysfunction-associated steatotic liver disease in people living with HIV and on antiretroviral treatment: A systematic review and meta-analysis protocol
    Sedibe, Amogelang
    Maswanganyi, Khanyisa
    Mzimela, Nomusa C.
    Gamede, Mlindeli
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [29] Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
    Mantovani, Alessandro
    Csermely, Alessandro
    Bilson, Josh
    Borella, Niccolo
    Enrico, Scoccia
    Pecoraro, Barbara
    Shtembari, Emigela
    Morandin, Riccardo
    Polyzos, Stergios A.
    Valenti, Luca
    Tilg, Herbert
    Byrne, Christopher D.
    Targher, Giovanni
    GUT, 2024, 73 (09) : 1554 - 1561
  • [30] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)